Stockreport

Summit: A Cautious Bet Backed By Anti-VEGF And Insider Buying [Seeking Alpha]

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF SMMT's Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism, with the potential to outperform the benchmarks. While ther [Read more]